Study Summary
This trial is comparing a less intense radiation therapy with 2 cycles of standard chemotherapy to the current standard chemoradiation for people with HPV positive and hypoxia negative T1-2, N1-2c oropharyngeal squamous cell carcinoma.
- Carcinoma, Squamous Cell
- Squamous cell carcinoma
- human papillomavirus
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 2 years (+/- 3 months)
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Arm B: HPV associated oropharyngeal carcinoma
1 of 2
Arm A: HPV associated oropharyngeal carcinoma
1 of 2
Experimental Treatment
300 Total Participants · 2 Treatment Groups
Primary Treatment: Cisplatin · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 27th, 2021
Last Reviewed: November 9th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.